Clinico-Genomic Database

The CGDB features:

100K+

linked patients

300+

genes

3 month

recency

Conduct disease-specific and disease-agnostic analyses

Our disease-agnostic datasets combine 20 disease-specific data models with a lighter-weight data model for all other histologies to enable robust pan-tumor analyses. Patient data across early through metastatic disease stages are included in a majority of our datasets.

Download fact sheet

20 deep disease-specific data models to meet your real-world clinico-genomic data needs

  • Acute Myeloid Leukemia
  • Advanced Bladder Cancer
  • Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Colorectal Cancer
  • Diffuse Large B-Cell Lymphoma
  • Advanced Endometrial Cancer
  • Follicular Lymphoma
  • Gastric/Esophageal/GEJ Cancer
  • Head and Neck Cancer
  • Hepatocellular Carcinoma
  • Mantle Cell Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Non-small Cell Lung Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Metastatic Prostate Cancer
  • Renal Cell Carcinoma
  • Small Cell Lung Cancer

Clinically meaningful cancer genomic data

Our linked Clinico-Genomics Database contains robust genomic profiling data across solid and liquid biopsies, utilizing circulating tumor (ct) DNA, and offers complex biomarker information such as tumor mutational burden (TMB), microsatellite instability (MSI) status, and PD-L1 results.

The role of real-world data in disease-agnostic drug development

This session showcases industry perspectives highlighted by pre- and post-market use cases to discuss the value of RWE across the disease-agnostic drug development life cycle.

Generate real-world evidence across the life cycle of a drug, pre- and post-launch

Flatiron real-world data has informed key clinical development decisions, supported clinical trial data in regulatory submissions, fulfilled post-marketing commitments, and enabled market access and payer decisions.

Learn more about Flatiron product use cases

The CGDB has enabled 100+ publications with:

15+

biopharma partners

25+

clinical organizations

25+

unique journals

Systematic pan-cancer analysis of mutation– treatment interactions using large real-world clinicogenomics data

Read publication

Survival Outcomes and Treatment Patterns in Patients With NFE2L2 and/or KEAP1 Mutation-Positive Advanced Squamous Cell NSCLC Using a Real-World Clinico-Genomic Database

Read publication

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer

Read publication

Derive real-world endpoints using our validated real-world outcome variables

Real-world overall survival (rwOS)

Conduct robust survival analyses for studies that may span natural history of disease to comparative effectiveness with our validated mortality variable.

See our real-world mortality validation study

Download the fact sheet

Real-world progression-free survival (rwPFS)

Analyze real-world progression-related endpoints across observational RWE studies with our validated real-world progression (rwP) variable.*

See our rwP validation study

Real-world response endpoints

Analyze real-world response-related endpoints to support clinical development or regulatory decision making with our validated real-world response (rwR) variable.*

See our rwR validation study

*available with certain subscriptions

Originally stemming from a high priority need for real-world data, we were able to foster a new collaboration with Flatiron and Foundation Medicine and utilize their large data source of rich clinical and genomic data representing a substantial proportion of community oncology patients nationally.

Interested in working with Flatiron
and Foundation Medicine real-world data?

Contact Us